| Literature DB >> 35424637 |
Hemanth Kumar Chanduluru1, Abimanyu Sugumaran1.
Abstract
Analytical research with adverse environmental impact has caused a severe rise in concern about the ecological consequences of its strategies, most notably the use and emission of harmful solvents/reagents into the atmosphere. Nowadays, industries are searching for the best reproducible methods. Voriconazole is a second-generation azole derivative used effectively in the treatment of Candida and Aspergillus species infections and oropharyngeal candidiasis in AIDS patients. Recently it has become the drug of choice in treating mucormycosis in several countries, which raises the need for production in large quantities. The present review deals with various recent important analytical techniques used to estimate voriconazole and its combination in pharmaceutical formulations and biological fluids. The methods show their own unique way of analyzing voriconazole in different matrices with excellent linearity, detection, and quantification limits. Additionally, this article deals with methods and solvents analyzed for their impact on the environment. This is followed by estimating the degree of greenness of the methods using various available assessment tools like analytical eco-scale, national environmental method index, green analytical procedure index, and AGREE metrics to confirm the environmental impact. The scores obtained with the evaluation tools depict the quantum of greenness for the reported methods and provide an ideal approach adopted for VOR estimation. Very few methods are eco-friendly, which shows that there is a need for the budding analyst to develop methods based on green analytical principles to protect the environment. This journal is © The Royal Society of Chemistry.Entities:
Year: 2022 PMID: 35424637 PMCID: PMC8982219 DOI: 10.1039/d1ra08858k
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 3.361
Fig. 1Structure of voriconazole.
Fig. 2Methods available for the estimation of VOR.
Fig. 3Analytical methods reported for VOR from 1997 to September 2021 (source: Google, PubMed, Taylor and Francis, Elsevier, Science Direct, and Scopus).
Fig. 4NEMI, GAPI, AES, and AGREE assessments for the official methods.
Spectroscopic techniques reported for determining VOR and their greenness assessment
| S. no. | Matrix of VOR | Reagents or solvents | Detection (nm) | Linearity (μg mL−1) | NEMI | GAPI | AES | AGREE | Ref. |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Bulk and tablet | MeOH | 252 | 5–80 |
|
| 8 + 0 + 2 + 5 = 15 |
|
|
|
| |||||||||
| 2 | Bulk and tablet | Milli Q pore water | 255 | 5–35 |
|
| 0 + 0 + 0 + 0 = 0 |
|
|
|
| |||||||||
| 3 | Tablet | MeOH | 256 | 5–30 |
|
| 8 + 0 + 2 + 5 = 15 |
|
|
|
| |||||||||
| 4 | Tablets | (1) 0.1 M HCl and tropaeoline ooo | (1) 500 | (1) 5.0–2 |
|
| 8 + 0 + 1 + 5 = 14 |
|
|
|
| |||||||||
| (2) pH 1.5 buffer and azo carmine-G | (2) 550 | (2) 10–50 |
|
| 8 + 0 + 1 + 5 = 14 |
| |||
|
| |||||||||
| 5 | Bulk powder and pharmaceutical dosage form | 0.1 N HCl | 256 | 10–60 |
|
| 8 + 0 + 1 + 5 = 14 |
|
|
|
| |||||||||
| 6 | Tablets | Phosphate buffers (pH 2.0, 4.0, 6.8, and 7.0) | 200–400 | 5–60 |
|
| 1 + 0 + 0 + 0 = 1 |
|
|
|
|
Greenness assessment of reported HPLC methods for determining VOR and its combinationsa
| S. no. | Drug substance | Stationary phase and mobile phase | Linearity (μg mL−1) |
| NEMI | GAPI | AES | AGREE | Ref. |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VOR | Merck LiChrospher 100 RP-8 (125 mm × 4.6 mm, 5 μm) | 20–100 | NA |
|
| 36 + 1 + 3 + 5 = 45 |
|
|
| 0.6% triethylamine (pH 6.0) : MeOH (50 : 50 v/v) | Eco score = 55 | ||||||||
| 2 | VOR | Chiral cel-OD (250 mm × 4.6 mm, 10 μm) | 25–200 | 21.06 |
|
| 20 + 1 + 3 + 5 = 29 |
|
|
|
| ES = 71 | ||||||||
| 3 | VOR | Diamonsil C18 column (250 mm × 4.6 mm, 5 μm) | 1–100 | 14.002 |
|
| 12 + 1 + 3 + 5 = 21 |
|
|
| ACN : water : CH3COOH (40 : 60 : 0.25 v/v/v) | ES = 79 | ||||||||
| 4 | VOR | C-18 Hypersil BDS column (250 mm × 4.6 mm, 5 μm) | 20–400 | 12.98 |
|
| 15 + 1 + 3 + 5 = 24 |
|
|
| Water : ACN : MeOH (50 : 25 : 25 v/v/v) | ES = 76 | ||||||||
| 5 | VOR | Hypersil C18 (250 mm × 4.6 mm, 5 μm) | 5–25 | NA |
|
| 4 + 1 + 3 + 5 = 13 |
|
|
| ACN : water (40 : 60 v/v) | ES = 87 | ||||||||
| 6 | VOR | Zorbax SB-C18 (250 mm × 4.6 mm, 5 μm) | 10–100 | 6.7 |
|
| 7 + 1 + 3 + 3 = 14 |
|
|
| Ammonium phosphate dibasic buffer (pH 6.0 with; 50 mM | ES = 86 | ||||||||
| 7 | VOR | Hypersil, C18 (250 mm × 4.6 mm, 5 μm) | 5–100 | 5.82 |
|
| 4 + 1 + 3 + 5 = 13 |
|
|
| Water : ACN (50 : 50 v/v) | ES = 87 | ||||||||
| 8 | VOR | Bondapak C18 (10 μm, 250 mm × 4.6 mm) | 6.0–60 | 7.3 |
|
| 4 + 1 + 3 + 3 = 11 |
|
|
| ACN : 0.05 M disodium hydrogen phosphate buffer (pH 5.5) (1 : 1 v/v) | ES = 89 | ||||||||
| 9 | VOR | Intersil ODS C18 (150 × 4.6 mm, 5 μm) | 7.94–11.91 ppm | 6.413 |
|
| 10 + 1 + 3 + 5 = 19 |
|
|
| Phosphate buffer, ACN and MeOH (65 : 30 : 5 v/v/v) | ES = 81 | ||||||||
| 10 | VOR | C18 G column (250 mm × 4.6 mm, 5 μm) | 10–50 | 5.36 |
|
| 4 + 1 + 3 + 5 = 13 |
|
|
| ACN and water (60 : 40 v/v) | ES = 87 | ||||||||
| 11 | VOR | Develosil C18 column (100 mm × 4.6 mm, 3 μm) | 12–100 | 2.5 |
|
| 4 + 1 + 3 + 5 = 13 |
|
|
| MP A: phosphate buffer 0.05 M (pH 4.5) and ACN (800 : 200% v/v) | ES = 87 | ||||||||
| MP B: CAN and water in the ratio 800 : 200% v/v | |||||||||
| A : B = 35 : 65 | |||||||||
| 12 | VOR | C18 column (150 mm × 4.6 mm, 5 μm) | 1 to 30 | 4.09 |
|
| 4 + 1 + 3 + 5 = 13 |
|
|
| ACN and ultrapure water (50 : 50 v/v) | ES = 87 | ||||||||
| 13 | VOR | Prontosil C-18 (250 mm × 4.6 mm, 5 μm) | 5 to 25 | 7.92 |
|
| 4 + 1 + 3 + 5 = 13 |
|
|
| Isopropyl alcohol : water (80 : 20 v/v) | ES = 87 | ||||||||
| 14 | VOR | Inertsil ODS 3V (150 mm × 4.6 mm, 5 μm) | NA | 21.78 |
|
| 17 + 1 + 3 + 5 = 26 |
|
|
| MP A: 0.05 M KH2PO4 (pH 2.5 buffer) | ES = 74 | ||||||||
| MP B: ACN : MeOH (90 : 10 v/v) | |||||||||
| 15 | VOR, UFLC | C8 Luna column (250 mm × 4.6 mm, 5 μm) | 0.5–50 | 3.02 |
|
| 5 + 0 + 3 + 3 = 11 |
|
|
| ACN : 0.01% CH3COOH (50 : 50 v/v) | ES = 89 |
VOR – voriconazole; MeOH – methanol; ACN – acetonitrile; FeCl3 – ferric chloride; KH2PO4 – potassium dihydrogen phosphate; NaOH – sodium hydroxide; HCl – hydrochloric acid; N – normal; NA – not available; LOQ – limit of quantification; LOD – limit of detection; mg mL−1 – microgram per millilitre; MP – mobile phase.
Green assessment for the reported HPTLC methods
| S. no. | Mobile phase | NEMI | GAPI | AES | AGREE | Ref. |
|---|---|---|---|---|---|---|
| 1 | MeOH : toluene (7 : 3 v/v) |
|
| 24 + 1 + 3 + 5 = 33 |
|
|
| ES = 67 | ||||||
| 2 | Triethylamine : MeOH : toluene (0.1 : 4 : 6 v/v/v) |
|
| 30 + 1 + 3 + 5 = 39 |
|
|
| ES = 61 | ||||||
| 3 | ACN : water (60 : 40 v/v) |
|
| 4 + 1 + 3 + 5 = 13 |
|
|
| ES = 87 | ||||||
| 4 | MeOH : toluene (2 : 8 v/v) |
|
| 24 + 1 + 3 + 5 = 33 |
|
|
| ES = 67 |
Analytical and greenness assessment data for the reported bioanalytical methodsa
| Drug and instrument | Sample | Extraction | Column | Linearity | NEMI | GAPI | AES | AGREE | Ref. |
|---|---|---|---|---|---|---|---|---|---|
| VOR, multidimensional HPLC with size-exclusion chromatography | Plasma | Sephadex G-25 superfine column of (100 × 10 mm ID) | Spherisorb ODS IMX (250 mm × 4.6 mm, 2.5 μm) | 10 to 3000 ng mL−1 |
|
| 15 + 1 + 3 + 5 = 24 |
|
|
| ACN : 0.1 M TEMED phosphate (pH 7.0) (42 : 58 v/v) | ES = 76 | ||||||||
| VOR, HPLC | Human plasma | With can | Kromasil C18 (250 mm × 4.6 mm, 5 μm) | 0.2–10 μg mL−1 |
|
| 5 + 1 + 3 + 3 = 12 |
|
|
| 0.04 M ammonium phosphate (pH 6.0 M) : ACN (1 : 1 v/v) | ES = 88 | ||||||||
| VOR, HPLC-ESI-MS | Human plasma | Protein precipitation | C18 column (50 mm × 2.1 mm, 3.5 μm) | 2.49–293 ng mL−1 |
|
| 4 + 2 + 3 + 3 = 12 |
|
|
| ACN : water (0.1% HCOOH) (40 : 60 v/v) | ES = 88 | ||||||||
| VOR, HPLC | Plasma | SPE through Bond Elute columns C18, 100 mg mL−1 | Luna 5 m C18 column (250 mm × 4.6 mm, 5 μm) | 0.2–10 μg mL−1 |
|
| 6 + 1 + 3 + 3 = 13 |
|
|
| ACN : TEMED (pH 7.4 using phosphoric acid) (45 : 55 v/v) | ES = 87 | ||||||||
| VOR, HPLC | Human plasma | Direct injection | Silica particles, bonded with a GFFP (150 mm × 4.6 mm, 5 μm) | 0.5–10 μg mL−1 |
|
| 5 + 1 + 3 + 3 = 11 |
|
|
| ACN : KH2PO4 (pH 6.0) (17 : 83 v/v) | ES = 88 | ||||||||
| VOR, LCMS | Plasma | Online solid-phase extraction | Waters Oasis HLB (25 mm × 2.0 mm, 2.1 μm) | 78–5000 mg L−1 |
|
| 6 + 2 + 3 + 3 = 14 |
|
|
| Water/methanol 95 : 5 (v/v) | Water : MeOH (95 : 5 v/v) | ES = 86 | |||||||
| VOR, HPLC | Plasma | LLE | Chromolithic RP 18 monolithic silica rod (100 mm × 4.6 mm) | 0.05–10 μg mL−1 |
|
| 11 + 1 + 3 + 3 = 18 |
|
|
| Tetrahydrofuran : ACN : NH4HCO3 (pH 5.8): (3 : 25 : 72 v/v/v) | ES = 82 | ||||||||
| VOR, HPLC-MS | Human plasma | Protein precipitation, automated SPE | LiCrospher 100 RP-18 (125 mm × 4 mm, 5 μm) | 78–5000 mg L−1 |
|
| 6 + 2 + 3 + 3 = 14 |
|
|
| Water : ACN (50 : 50 v/v) | ES = 86 | ||||||||
| VOR, LC-MS/MS | Rat plasma | With MeOH | Shim-pack HPLC column (150 mm × 4.6 mm, 5 μm) | 50–2500 ng mL−1 |
|
| 14 + 2 + 3 + 3 = 22 |
|
|
| ACN : HCOOH : water (60 : 0.05 : 40 v/v/v) | ES = 78 | ||||||||
| VOR, HPLC | Rat and beagle dog plasma | With MeOH : ACN (1 : 2) | Diamonsil C18 (250 mm × 4.6 mm, 5 μm) | 0.10–50.0 μg mL−1 |
|
| 15 + 1 + 3 + 3 = 22 |
|
|
| Water : ACN : CH3COOH (pH 4.0) (45 : 55 : 0.25 v/v/v) | ES = 78 | ||||||||
| VOR, HPLC | Serum | Vortexed with mobile phase | Nova-Pak CN-HP (100 mm × 3.9 mm, 4 μm) | 0.4–10.0 mg L−1 |
|
| 15 + 1 + 3 + 5 = 24 |
|
|
| 15% ACN (0.1% | ES = 76 | ||||||||
| VOR, HPLC | Plasma | With can | C18 column (150 mm × 4.6 mm) | 0.25–16 mg L−1 |
|
| 10 + 1 + 3 + 3 = 17 |
|
|
| 50% MeOH : 0.01 M CH3COONa (pH 5.0 v/v) | ES = 83 | ||||||||
| VOR, HPLC | Serum and plasma | LLE | Supelcosil LC-18-DB (25 mm × 4.6 mm, 5 μm) | 0.1–20 μg mL−1 |
|
| 7 + 1 + 3 + 3 = 14 |
|
|
| MP A: 10% ACN : 90% 0.01 M K3PO4 pH 3.0 (v/v) | ES = 86 | ||||||||
| MP B: 100% ACN | |||||||||
| VOR, HPLC-FLD | Human plasma and saliva | With | LUNA C18 (250 mm × 3.0 mm, 5 μm) | 0.1–10 μg mL−1 |
|
| 17 + 1 + 3 + 3 = 24 |
|
|
| ACN : 0.01 M KH2PO4 buffer (0.01 M TEMED pH 6.8) (45 : 55 v/v) | ES = 76 | ||||||||
| VOR, HPLC | Plasma | With can | LiChrospher-100 RP-18 (125 × 4 mm, 5 μm) | 1.5–10 μg mL−1 |
|
| 7 + 1 + 3 + 3 = 14 |
|
|
| 0.04 M ammonium phosphate (pH 6.0) : ACN (60 : 40 v/v) | ES = 86 | ||||||||
| VOR, HPLC | Serum | With MeOH | Hibar, LiChrospher C8 RP column (100 mm × 5 mm, 5 μm) | 0.26 to 10.1 μg mL−1 |
|
| 19 + 1 + 3 + 3 = 26 |
|
|
| 0.04 M KNaPO4 (pH 6.0) : water : ACN (45 : 2.5 : 52.5 v/v/v) | ES = 74 | ||||||||
| VOR, LCEIMS | Aqueous humour | NA | C18 column (300 mm × 5 mm, 15 μm) | 0.02–30 μg mL−1 |
|
| 15 + 2 + 3 + 3 = 23 |
|
|
| 70% ACN : 30% water : 0.01% TFA | ES = 77 | ||||||||
| VOR, HPLC-ESI-MS | Plasma | Protein precipitation | C18 column (50 mm × 2.1 mm, 3.5 μm) | 2.49–293 ng mL−1 |
|
| 10 + 2 + 3 + 3 = 18 |
|
|
| ACN : water (0.1% HCOOH) 40 : 60 v/v | ES = 82 | ||||||||
| VOR, LC-MS/MS | Serum | Vortexed and then centrifuged | C18 column (100 mm × 3.0 mm, 2.6 μm) | 0.1 and 10.0 μg mL−1 |
|
| 7 + 2 + 3 + 3 = 15 |
|
|
| MP A: 0.1% HCOOH : 2 mM CH3COONH4 | ES = 85 | ||||||||
| MP B: 2 mM CH3COONH4, 0.1% HCOOH in MeOH | |||||||||
| VOR | Bovine serum | Centrifugation | HyPURITY Aquastar C18 (50 mm × 2.1 mm, 5 μm) | 0.10–10.08 mg L−1 |
|
| 7 + 1 + 3 + 3 = 14 |
|
|
| MP A: CH3COOH, CH3COONH4 and TFA | ES = 86 | ||||||||
| MP B: water : MeOH | |||||||||
| VOR, HPLC | Human serum | With ice-cold ACN | SunFire C18 (150 mm × 4.6 mm, 5 μm) | 0.25–16.0 μg mL−1 |
|
| 6 + 1 + 3 + 3 = 13 |
|
|
| ACN : ultrapure water (70 : 30 v/v) | ES = 87 | ||||||||
| VOR, LC-MS-MS | Human serum | Protein precipitated with 200 μL of ACN | EC-C18 (50 mm × 3.0 mm, 2.7 μm) | 0.05–10 μg mL−1 |
|
| 5 + 1 + 3 + 3 = 12 |
|
|
| ACN : 0.1% HCOOH in 10 mM CH3COONH4 (50 : 50 v/v) | ES = 88 | ||||||||
| VOR, HPLC-FLD | Human plasma and serum | Protein precipitation and ACN extraction | ODS HYPERSIL column (250 mm × 4.6 mm, 5 μm) | 0.1–10 μg mL−1 |
|
| 5 + 1 + 3 + 3 = 12 |
|
|
| 0.1 M CH3COONH4 solution, ACN and TFA (409 : 590 : 1 v/v/v) | ES = 88 | ||||||||
| VOR, HPLC | Human blood | With hexane and ethyl acetate | Eclipse X DB C18 (4.5 mm × 5 μm) | 1.0 to 8.0 μg mL−1 |
|
| 16 + 1 + 3 + 3 = 23 |
|
|
| ACN : water (50 : 50 v/v) | ES = 77 | ||||||||
| VOR, HPLC-FLD | Human serum | Protein precipitation with ACN | LiChrospher RP-18e column (125 mm × 4 mm, 5 μm) | VOR 0.2–20.0 μg mL−1 |
|
| 13 + 1 + 3 + 3 = 20 |
|
|
| 10 mM KH2PO4 (10 mM of TEMED pH 6.5) : ACN 65 : 35 (v/v) | ES = 80 | ||||||||
| VOR, HPLC | Plasma | Ultrafiltration method with tween 80 | LiChrospher (125 mm × 4 mm, 5 μm) | 0.05–10.0 μg mL−1 |
|
| 15 + 1 + 3 + 3 = 22 |
|
|
| ACN : 10 mM KH2PO4 (10 mM of TEMED) (pH 6.5) (35 : 65 v/v) | ES = 78 | ||||||||
| VOR, LCMS | Human plasma | Vortexed and centrifuged by using MeOH | C18 column (100 mm × 2.1 mm × 3.5 μm) | 0.1–10.0 μg mL−1 |
|
| 15 + 1 + 3 + 5 = 24 |
|
|
| MeOH : 0.1% HCOOH (70 : 30 v/v) | ES = 76 | ||||||||
| VOR, surface-enhanced Raman spectroscopy | Plasma | Centrifugation | Diamonsil C18 | 0.41–6.12 μg mL−1 |
|
| 4 + 1 + 3 + 3 = 11 |
|
|
| ACN : 0.1% HCOOH (43 : 57 v/v) | ES = 89 | ||||||||
| VOR, HPLC | Humans | Centrifugation | C18 column (250 mm × 4.6 mm, 3.5 μm) | 0.125–10 μg mL−1 |
|
| 5 + 1 + 3 + 3 = 12 |
|
|
| ACN : 0.05 M CH3COONH4 : MeOH (20 : 40 : 40 v/v/v) | ES = 88 | ||||||||
| VOR, HPLC | Beagle plasma | Vortexed and centrifuged by using MeOH | Venusil XBP C18 (250 mm × 4.6 mm, 5 μm) | 200–100 000 ng mL−1 |
|
| 15 + 1 + 3 + 3 = 22 |
|
|
| ACN : 20 mM KH2PO4 (65 : 35 v/v) | ES = 78 | ||||||||
| VOR, ITC, HPLC | Human serum | Heptane–isoamyl alcohol (90 : 10 v/v) | Zorbax SB-C18 (250 mm × 4.6 mm, 5 μm) | 0.5–5.0 μg mL−1 |
|
| 19 + 1 + 3 + 3 = 26 |
|
|
| 50 mM phosphate buffer (pH 6.0 with 1 M KOH) : MeOH : ACN (35 : 20 : 45) (v/v/v) | ES = 74 | ||||||||
| VOR, PSC, HPLC | Human plasma | Hexane–methylene chloride (70 : 30 v/v) | C8 plus (250 mm × 3 mm, 5 μm) | VOR 0.2–10.0 mg L−1 |
|
| 15 + 1 + 3 + 3 = 22 |
|
|
| Water : 0.04 M NaKHPO4 : ACN (2.5 : 45 : 52.5 v/v/v) | PSC 0.05–10.0 mg L−1 | ES = 78 | |||||||
| VOR, PSC, HPLC | Human plasma | LLE with diethyl ether | ReproSil-Pur Basic C18 (150 mm × 2 mm × 5 μm) | 1.0–20.0 μg mL−1 |
|
| 7 + 1 + 3 + 3 = 14 |
|
|
| ACN : 0.09 M monobasic ammonium phosphate (pH 5.3) (50 : 50 v/v) | ES = 86 | ||||||||
| VOR, ITC, PSC, HPLC-MS | Human plasma | Protein precipitation extraction with ACN | C18 Atlantis T-3 (150 mm × 4.6 mm, 5 μm) | ITC 0.04–1.18 μg mL−1 |
|
| 6 + 1 + 3 + 3 = 13 |
|
|
| Water (0.05% HCOOH) : ACN 50 : 50 and 20 : 80 from 6.5 min | PSC 0.04–3.20 μg mL−1 | ES = 87 | |||||||
| VOR 0.09–8.32 μg mL−1 | |||||||||
| VOR, PSC, FLZ, ITZ, LC-MS/MS | Human serum | Protein precipitation | Phenomenex Luna C8 (50 mm × 2 mm, 3 μm) | VOR 0.01–10 μg mL−1 |
|
| 5 + 1 + 3 + 3 = 11 |
|
|
| MP A: 0.1% HCOOH and 10 mM HCOONH4 in water | POS 0.02–40 μg mL−1 | ES = 89 | |||||||
| MP B: 0.1% HCOOH in ACN | FLU 0.2–200 μg mL−1 | ||||||||
| ITZ 0.02–20 μg mL−1 | |||||||||
| VOR, TFL, HPLC | Plasma | Without extraction | Shim-Pack XR-ODS (100 mm × 2.0 mm, 2.2 μm) | 0.1 μg mL−1 and 0.5 μg mL−1 |
|
| 4 + 1 + 0 + 1 = 6 |
|
|
| 50 mM phosphate buffer (pH 3.0)/propylene carbonate : ethanol (10 : 90 v/v) | ES = 94 | ||||||||
| VOR, ITC, PSC, UPLC-MS/MS | Human plasma | Centrifugation | BEH C18 column (50 mm × 2.1 mm, 1.7 μm) | VOR 0.13 and 6.54 mg L−1 |
|
| 7 + 1 + 3 + 3 = 14 |
|
|
| MP A: 10 mM CH3COONH4 in water and 0.1% HCOOH | POS 0.16 and 5.66 mg L−1 | ES = 86 | |||||||
| MP B: MeOH and 0.1% HCOOH | ITC 0.18 and 3.64 mg L−1 | ||||||||
| VOR, IMB, UPLC-MS/MS | Rat plasma | Protein precipitation by can | Acquity UPLC BEH C18 column (2.1 mm × 50 mm, 1.7 μm) | Imatinib, |
|
| 6 + 1 + 3 + 3 = 13 |
|
|
| ACN : 0.1% HCOOH in water (50 : 50 v/v) | VOR, | ES = 87 |
VOR – voriconazole; HPLC – high-performance liquid chromatography; R – retention time; SPE – solid-phase extraction; HCOOH – formic acid; KH2PO4 – potassium dihydrogen phosphate; NaH2PO4 – sodium dihydrogen phosphate; DAP – daptomycin; MeOH – methanol; ACN – acetonitrile; ITC – itraconazole; PSC – posaconazole; TED – tedizolid; LLE – liquid–liquid extraction; FLZ – fluconazole; IMB – imatinib; TFL – tadalafil; LC-MS/MS – liquid chromatography-tandem mass spectrometry; TEMED – N,N,N,N-tetramethyl ethylene diamine; K3PO4 – potassium phosphate; HPLC-FLD high-performance liquid chromatography fluorescence detection; GPPP – glycine phenylalanine–phenylalanine peptide.
Green assessment for the reported miscellaneous methods
| S. no. | Method and solvent/chemicals | NEMI | GAPI | AES | AGREE | Ref. |
|---|---|---|---|---|---|---|
| 1 | HPLC AQbD |
|
| 8 + 1 + 3 + 5 = 17 |
|
|
| 50 : 50 v/v ACN and water | ES = 83 | |||||
| 2 | Sweeping-micellar electrokinetic chromatography |
|
| 2 + 1 + 0 + 0 = 3 |
|
|
| 110 mM sodium dodecyl sulfate, 20% ACN, and 40 mM phosphoric acid | ES = 97 | |||||
| 3 | Differential pulse polarography (DPP) |
|
| 2 + 1 + 0 + 0 = 3 |
|
|
| 0.01 M KH2PO4 buffer (pH 4.5) | ES = 97 | |||||
| 4 | GCMS |
|
| 12 + 3 + 3 + 5 = 23 |
|
|
| Cold methanol, ethyl acetate, derivatization by using BSTFA | ES = 77 | |||||
| 5 | PSMS |
|
| 0 + 1 + 0 + 0 = 1 |
|
|
| ES = 99 | ||||||
| 6 | Microbiological technique |
|
| 0 + 0 + 0 + 0 = 1 |
|
|
| ES = 100 | ||||||
| 7 | RP-HPLC |
|
| 12 + 1 + 0 + 3 = 16 |
|
|
| AQbD | ES = 84 | |||||
| ACN and 0.05% acetic acid (pH 4) (50 : 50 v/v) |
Fig. 5Organic modifiers used by reported methods in analyzing VOR in HPLC.
Fig. 6Organic modifiers used in the developed methods for analyzing VOR in biological matrixes.